- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02215304
Safety and Tolerance Study of Three Probiotic Strains in Infants (PROBINFANT)
A Randomized, Double-blind, Placebo-controlled Intervention Study to Assess the Safety and Tolerance Effect of Three Probiotic Strains in Infants
Study Overview
Status
Conditions
Detailed Description
Subjects' parents or legal tutors will be contacted for voluntary participation and a written informed consent will be obtained.
The study visits will take place either in the hospital or primary health center.
During Visit 1, inclusion in- and exclusion criteria will be checked and information on demographic profile, subject characteristics, feeding option, relevant medical history, medication and nutritional supplements will be recorded. Weight and length and head circumference measurements of the infant will be made. The researcher will explain to the parents that during the first 2 weeks of participation in the study the infant must not intake any probiotic supplements (run-in ). Parents will be instructed to collect and send and/or store fecal and urine samples before starting the study. In addition they will be instructed to collect and send and/or store fecal and urine samples after the initial run-in period (2 weeks), after the product intake period (8 weeks) and after the final wash out period (2 weeks).
During Visit 2, subjects will be randomly allocated to receive either one of the test products or the placebo. Body weight and length will be measure. The researcher will review with the parents the study diary in detail, how to record data on gastrointestinal tolerance, stool frequency and stool characteristics, respiratory symptoms, diagnosed infections, sleeping and crying habits, changes in sleeping pattern, fever episodes, unscheduled visits resulting from suspected infection or a health problem and antibiotic prescription. The researcher will explain the procedure of administering the study product to the infant and anticipated phone calls. The parents will be instructed to start intake of the product as soon as possible after the collection of fecal and urine samples.
During product intake period (8 weeks) subject's parents will be called weekly by someone from the Study Team (Phone call 1, 2, 3, 4, 5, 6, 7). During the phone call relevant data related to possible Adverse Events (AEs) or Serious Adverse Events (SAEs) will be collected. Parents will be asked about infant's well-being (fever episodes, rashes, diarrhea, visits to the doctor, antibiotic prescription, etc.). Issues regarding diary completion, if any, will be discussed. During the Phone call 7 parents will be instructed to collect and send and/or store fecal and urine samples in one of the days prior to the third visit.
At the third visit (Visit 3, 8 weeks after product intake period), body weight and length will be measured and relevant data will be collected with respect to health and well-being aspect of the infant and AE or SAE (fever episodes, rashes, diarrhea, visits to the doctor, antibiotic prescription, etc.). Completed diaries and fecal and urine samples will be collected. Parents will be explained that for the last 2 weeks of participation in the study their infants could not intake any probiotic supplement (final wash out period). Parents will be instructed to collect and send and/or store fecal and urine samples in one of the days prior to the next visit (Visit 4).
During visit 4, after the final wash out period, body weight and length will be measured and relevant data will be collected with respect to health and well-being aspect of the infant and AEs or SAEs (fever episodes, rashes, diarrhea, visits to the doctor, antibiotic prescription, etc.). Completed diaries and samples will be collected.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Madrid, Spain, 28046
- Hospital Universitario La Paz
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy term infants between 3-12 months old
- Written informed consent from at least one parent or the legal tutor.
Exclusion Criteria:
- Short bowel syndrome or any GI surgery.
- Impaired intestinal epithelial barrier (e.g. diarrheal illness, intestinal inflammation).
- Metabolic disorders (diabetes, lactose intolerance).
- Immunodeficiency.
- Heart failure and cardiac medical history (e.g. artificial heart valve, medical history of infectious endocarditis, cardiac malformation, rheumatic fever).
- Surgery within one month prior to inclusion (Visit 1/ week 0).
- Antibiotic prescription 1 week before inclusion (Visit 1/ week 0) and during run-in period (Visit 2/ week 2).
- Investigator's uncertainty about the willingness or ability of the infant's parents to comply with the protocol requirements.
- Participation in any other clinical trial within two weeks prior to entry into the study.
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Bifidobacterium longum R0033
Bifidobacterium longum ssp infantis R0033, 3*10E9 colony forming units (CFU) in 1 sachet per day to be diluted in 10 mL water by mouth for eight weeks
|
12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time. During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3*10E9 colony forming units (CFU) |
Active Comparator: Lactobacillus helveticus R0052
Lactobacillus helveticus R0052, 3*10E9 colony forming units (CFU) in 1 sachet per day to be diluted in 10 mL water by mouth for eight weeks
|
12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time. During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3*10E9 colony forming units (CFU) |
Active Comparator: Bifidobacterium bifidum R0071
Bifidobacterium bifidum R0071, 3*10E9 colony forming units (CFU) in 1 sachet per day to be diluted in 10 mL water by mouth for eight weeks
|
12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time. During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3*10E9 colony forming units (CFU) |
Placebo Comparator: Placebo
potato starch 1 sachet per day to be diluted in 10 mL water by mouth for eight weeks
|
12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time. During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3*10E9 colony forming units (CFU) |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerance will be evaluated according to infant growth (weight, height and head circumference)
Time Frame: 12 weeks
|
growth will be evaluated considering weight, height and head circumference, at four different time points during study: 1st measure will be at screening visit (visit 1/week 0), 2nd measure will be after the run-in period and before starting intervention (visit 2/ week 2), 3rd measure will be after the eight weeks of intervention (visit 3/ week 10) and the 4th measure will be two weeks later (visit 4/week 12).
|
12 weeks
|
Adverse Event and/or Serious Adverse Event
Time Frame: 10 weeks
|
Adverse Event and/or Serious Adverse Event will be recorded daily by parents and notified to investigator within 24hrs., in particular gastro-intestinal symptoms, fever and rashes.
|
10 weeks
|
Fecal characteristics
Time Frame: 10 weeks
|
Fecal characteristics (stool frequency, stool consistency, stool amount and stool color) will be recorded daily by parents according to the "Amsterdam scale" and notified weekly to investigators.
|
10 weeks
|
Use of medication
Time Frame: 12 weeks
|
Medication used (antibiotics, etc) will be recorded daily by parents and notified weekly to investigators.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Urine concentration of D-lactic acid.
Time Frame: 12 weeks
|
D-lactic acid will be measured in urine samples at 4 different time points (weeks 0, 2, 10 and 12).
|
12 weeks
|
Changes in sleep and crying patterns
Time Frame: 10 weeks
|
Changes in sleep and crying patterns will be recorded daily by parents and notified weekly to investigators.
|
10 weeks
|
Immune compounds in fecal samples
Time Frame: 8 weeks
|
Immunoglobulins (Ig) A, G1, G2, G3, G4 and M, cytokines, chemokines and growth factors such as interleukins (IL) 1β, 2, 4, 5, 6, 7, 8, 10, 12, 13, and 17, interferon-γ (INF-γ), tumor necrosis factor-α (TNF-α), growth related oncogene-α (GRO-α), macrophages chemoattractant protein-1 (MCP-1), macrophages inflammatory protein-1β (MIP-1β), granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophages colony stimulating factor (GM-CSF) and Calprotectin concentrations will be measured at two time points, before and after the study probiotic intake (weeks 0 and 10).
|
8 weeks
|
Composition of fecal microbiota
Time Frame: 8 weeks
|
Composition of fecal microbiota will be assessed at two different time points, before and after the intervention period
|
8 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Felix Omeñaca, MD, PhD, Hospital Universitario La Paz
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LALLEM-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Body Weight
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)RecruitingWeight Loss | Weight, BodyUnited States
-
Oslo University HospitalMayo Clinic; Sorlandet Hospital HF; The Hospital of Vestfold; University of TwenteActive, not recruiting
-
Fred Hutchinson Cancer CenterCompletedWeight Loss | Weight, BodyUnited States
-
Pusan National University HospitalCompletedWeight Change, Body
-
Xinhua Hospital, Shanghai Jiao Tong University...Not yet recruiting
-
Erik Ramirez LopezCompletedWeight Loss | Body CompositionMexico
-
University of LeedsDietary Assessment LtdRecruitingWeight Loss | Colorectal Surgery | Weight Change, Body | Gastroenterology SurgeryUnited Kingdom
-
University of TennesseeMayo Clinic; National Institute of Diabetes and Digestive and Kidney Diseases...CompletedSmoking Cessation | Weight Change, BodyUnited States
-
Virta HealthActive, not recruiting
-
University of Colorado, DenverNational Heart, Lung, and Blood Institute (NHLBI)Enrolling by invitationObesity | Weight Change, BodyUnited States
Clinical Trials on Bifidobacterium longum ssp infantis R0033
-
University of FloridaLallemand Human NutritionCompleted
-
University of ManitobaLallemand Health SolutionsWithdrawnInfant, Premature, Diseases
-
University of ReadingUnknown
-
Institut Rosell LallemandBioFortisCompletedInfectious Episodes (ENT, Gastro-intestinal and Pulmonary)France
-
Stanford UniversityInternational Centre for Diarrhoeal Disease Research, Bangladesh; Thrasher...Completed
-
Federico II UniversityCompletedIrritable Bowel Syndrome | Dyspepsia ChronicItaly
-
National Health Service, United KingdomFerring Pharmaceuticals; Hull University Teaching Hospitals NHS Trust; North... and other collaboratorsCompleted
-
International Centre for Diarrhoeal Disease Research...CompletedSevere Acute MalnutritionBangladesh
-
Region SkaneCompleted
-
University of California, DavisEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedFecal Microflora in the Formula Fed Premature InfantUnited States